133 related articles for article (PubMed ID: 27783287)
1. Sensitivity of C6 Glioma Cells Carrying the Human Poliovirus Receptor to Oncolytic Polioviruses.
Sosnovtseva AO; Lipatova AV; Grinenko NF; Baklaushev VP; Chumakov PM; Chekhonin VP
Bull Exp Biol Med; 2016 Oct; 161(6):821-825. PubMed ID: 27783287
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Activity of the Vaccine Strain of Type 3 Poliovirus on the Model of Rat Glioma C6 Cells.
Sosnovtseva AO; Zheltukhin AO; Lipatova AV; Chumakov PM; Chekhonin VP
Bull Exp Biol Med; 2019 May; 167(1):111-115. PubMed ID: 31177454
[TBL] [Abstract][Full Text] [Related]
3. Poliovirus receptor CD155-targeted oncolysis of glioma.
Merrill MK; Bernhardt G; Sampson JH; Wikstrand CJ; Bigner DD; Gromeier M
Neuro Oncol; 2004 Jul; 6(3):208-17. PubMed ID: 15279713
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Foreman PM; Friedman GK; Cassady KA; Markert JM
Neurotherapeutics; 2017 Apr; 14(2):333-344. PubMed ID: 28265902
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Cell Receptors and Tumor Cell Sensitivity to Oncolytic Enteroviruses.
Lipatova AV; Le TH; Sosnovtseva AO; Babaeva FE; Kochetkov DV; Chumakov PM
Bull Exp Biol Med; 2018 Nov; 166(1):58-62. PubMed ID: 30450519
[TBL] [Abstract][Full Text] [Related]
6. Enterovirus A71 Oncolysis of Malignant Gliomas.
Zhang X; Wang H; Sun Y; Qi M; Li W; Zhang Z; Zhang XE; Cui Z
Mol Ther; 2020 Jun; 28(6):1533-1546. PubMed ID: 32304669
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus.
Atsumi S; Matsumine A; Toyoda H; Niimi R; Iino T; Nakamura T; Matsubara T; Asanuma K; Komada Y; Uchida A; Sudo A
Int J Oncol; 2012 Sep; 41(3):893-902. PubMed ID: 22692919
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model.
Toyoda H; Yin J; Mueller S; Wimmer E; Cello J
Cancer Res; 2007 Mar; 67(6):2857-64. PubMed ID: 17363609
[TBL] [Abstract][Full Text] [Related]
9. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses.
Cello J; Toyoda H; Dejesus N; Dobrikova EY; Gromeier M; Wimmer E
J Med Virol; 2008 Feb; 80(2):352-9. PubMed ID: 18098139
[TBL] [Abstract][Full Text] [Related]
10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
11. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
Walton RW; Brown MC; Sacco MT; Gromeier M
J Virol; 2018 Oct; 92(19):. PubMed ID: 29997212
[TBL] [Abstract][Full Text] [Related]
12. [Oncolytic viruses for therapy of malignant glioma].
Sosnovtceva AO; Grinenko NF; Lipatova AV; Chumakov PM; Chekhonin VP
Biomed Khim; 2016 May; 62(4):376-90. PubMed ID: 27562991
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic viral therapy of malignant glioma.
Parker JN; Bauer DF; Cody JJ; Markert JM
Neurotherapeutics; 2009 Jul; 6(3):558-69. PubMed ID: 19560745
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
15. Polioviruses that bind a chimeric Pvr-nectin-2 protein identify capsid residues involved in receptor interaction.
Lin Y; Racaniello VR
Virology; 2017 Oct; 510():305-315. PubMed ID: 28800489
[TBL] [Abstract][Full Text] [Related]
16. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype.
Dobrikova EY; Broadt T; Poiley-Nelson J; Yang X; Soman G; Giardina S; Harris R; Gromeier M
Mol Ther; 2008 Nov; 16(11):1865-72. PubMed ID: 18766173
[TBL] [Abstract][Full Text] [Related]
17. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
Harber J; Bernhardt G; Lu HH; Sgro JY; Wimmer E
Virology; 1995 Dec; 214(2):559-70. PubMed ID: 8553558
[TBL] [Abstract][Full Text] [Related]
18. Selective isolation of poliovirus in recombinant murine cell line expressing the human poliovirus receptor gene.
Hovi T; Stenvik M
J Clin Microbiol; 1994 May; 32(5):1366-8. PubMed ID: 8051271
[TBL] [Abstract][Full Text] [Related]
19. [Oncolytic properties of some orthopoxviruses, adenoviruses and parvoviruses in human glioma cells].
Razumov IA; Sviatchenko VA; Protopopova EV; Kochneva GV; Kiselev NN; Gubanova NV; Shilov AG; Mordvinov VA; Netesov SV; Chumakov PM; Loktev VB
Vestn Ross Akad Med Nauk; 2013; (12):4-8. PubMed ID: 24741936
[TBL] [Abstract][Full Text] [Related]
20. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Yamamoto S; Deckter LA; Kasai K; Chiocca EA; Saeki Y
Gene Ther; 2006 Dec; 13(24):1731-6. PubMed ID: 16871231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
